Mar. 13 at 5:10 PM
$APRE I reckon, given the latest trial results, shorts are more aware of its upside potential than the overall market. They appear to have refrained from shorting it since mid-February, and the available borrowable shares have mostly remained above 600K, not far from the recent maximum of 850K.
Based on the news, there may be a breakthrough ahead, provided that new positive results are obtained over the next phases of trials.
Meanwhile, on the daily chart, both a double bottom and a falling wedge remain in progress, indicating potential targets of
$2.43 and
$5.27, respectively, if validated (not advice)
